

JUL 14 2004

OFFICIAL



MYRIAD

MYRIAD GENETICS, INC.
320 WAKARA WAY
SALT LAKE CITY, UT 84108
www.myriad.com

To: United States Patent and Trademark Office	
Company:	
Fax: 703-872-9306	
From: Jonathan Baker	
email: JBAKER@myriad.com	
Direct Phone: 801-883-3204	Fax: 801-883-3871

DATE: July 14, 2004 NUMBER OF PAGES : 3 (Including cover)

Attached is an Official Communication for:

Attorney Docket No. 1804.10 (formerly 2318-288-II)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CIMBORA et al.)	Group Art Unit: 1647
Serial No.: 10/035,344)	
Filed: January 4, 2002)	
For: Protein-Protein Interactions)	Examiner: Robert Landsman

Respectfully submitted,

Jonathan A. Baker

Reg. No. 49,022

CERTIFICATE OF FACSIMILE

Date of Fax: July 14, 2004

I hereby certify that this paper or fee is being faxed on the date indicated above to the commissioner for Patents at fax number 703-872-9306.

Jonathan A. Baker7/14/04
Date

THE DOCUMENTS ACCOMPANYING THIS TRANSMISSION CONTAIN INFORMATION THAT IS CONFIDENTIAL. THIS INFORMATION IS INTENDED TO BE FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ON THIS TRANSMISSION SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, BE AWARE THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR USE OF THE CONTENTS OF THE INFORMATION IS PROHIBITED BY LAW. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE NOTIFY US BY TELEPHONE IMMEDIATELY SO THAT WE CAN ARRANGE FOR THE RETRIEVAL OF THE ORIGINAL DOCUMENT AT NO COST TO YOU.

JUL 14 2004

OFFICIAL

Attorney Docket No. 1804.10 (formerly 2318-288-ID)PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CIMBORA et al.)	Group Art Unit: 1647
Serial No.: 10/035,344)	
Filed: January 4, 2002)	
For: Protein-Protein Interactions)	Examiner: Robert Landsman

July 14, 2004

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22213-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:


In response to the Office Action dated June 14, 2004, in which a restriction requirement was set forth, Applicants elect, with traverse, Group VII (claims 46-50 and 53) drawn to a method for screening drug candidates.

Applicants traverse the restriction requirement on the grounds that there is not a serious burden on the Examiner to examine the inventions carved into Groups I-XVI. All of the claims of Groups I-XVI relate to affecting a protein complex having AKT1. As such, searching the subject matter of one group necessarily searches the other group. The M.P.E.P. § 803 states that an application must be examined on its merits even if it has independent or distinct inventions, as long as a serious burden is not put upon the examiner to search and examine the application. Applicants respectfully request withdrawal of the restriction requirement.

It is not believed that any extension of time, or any fee is required in connection with this communication. However, if an extension of time (and extension fee) or fees are required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees or credit any overpayment to Deposit Account No. 50-1627.

In re Application of: CIMBORA et al.
Serial No.: 10/035,344
Filed: January 4, 2002
Page 2

Respectfully submitted,



Jonathan Baker
Registration No. 49,022

Intellectual Property Department
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-584-3640

CERTIFICATE OF FACSIMILE

Date of Fax: July 14, 2004

I hereby certify that this paper or fee is being faxed on the date indicated above to the Commissioner for Patents at fax number 703-892-9306.


Jonathan Baker

7/14/04
Date

\\Barrister\Intellectual Property\Patent Prosecution\1800-1899\1804\1804.10\1804.10 2004-07-14 RESP-RESTR.doc